Galera Therapeutics, Inc.

Overview

• IndustryPharmaceutical Preparations¹
• HeadquartersMalvern, Pennsylvania¹
• Incorporated inDE²
• Business address101 Lindenwood Drive, Suite 225, Malvern, Pa 19355²
• Filer categoryNon-accelerated filer, Smaller reporting company²
• Legal formCorporation

See how the biggest companies compare on our leaderboards

We are a biopharmaceutical company that historically was focused on developing a portfolio of small molecule superoxide dismutase (SOD) mimetics to improve radiotherapy in cancer, primarily by reducing one of the most common side effects of radiotherapy, severe oral mucositis (SOM). In October 2025 we sold our assets related to avasopasem and rucosopasem and all other dismutase mimetics assets to Biossil, Inc. (Biossil), a privately-held company based in Toronto, Canada. In connection with selling these assets, we assigned and Biossil assumed all rights and obligations under the Royalty Agreement with Blackstone Life Sciences (Blackstone), as described below. We received consideration from Biossil in the form of an upfront payment of $3.5 million and are eligible to receive further payments upon the achievement of future regulatory and commercial milestones and we received contingent val…⁴ From its latest annual report

Corporate structure

Galera Therapeutics, Inc. sits at the top of its group. 3 entities, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Built from subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Galera Therapeutics, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

Investments

Intangibles and goodwill

Properties, in its own words

Our principal office is located at 101 Lindenwood Drive, Suite 225, Malvern, Pennsylvania 19355, where we lease office space under a month-to-month lease.

Item 2 of the 10-K filed Mar 19, 2026.⁴

Leadership

Who has led Galera Therapeutics, Inc., and when. Pick a name to see everywhere that person has worked.

• Chief executive officerMel Sorensen Nov 6, 2019 to now¹⁴
• PresidentMel Sorensen Nov 6, 2019 to now¹⁴
• Chief financial officerChris Degnan Nov 6, 2019 to Mar 14, 2023¹⁵
• Chief operating officerRobert A. Beardsley Nov 6, 2019 to Feb 28, 2023¹⁶

Named in SEC Form D filings

People the company listed in its private-offering notices.

• DirectorMichael R. Friedman named Jan 13, 2025 to Jan 14, 2025³⁰

Subsidiaries and ownership

Subsidiaries (Exhibit 21)

• Galera Labs, LLC Missouri, United States³
• Nova Pharmaceuticals Operating, LLC Delaware, United States³

The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.

Timeline

1. Aug 4, 20268-K Entered a material agreement; Completed an acquisition or sale; Listing notice or transfer³¹
2. Jul 31, 20268-K Unregistered sale of shares; Regulation FD disclosure³²
3. Jul 13, 20268-K Change to shareholders' rights; Bylaws or fiscal year changed³³
4. Jul 7, 20268-K Other events³⁴
5. May 19, 20268-K Other events³⁵
6. May 15, 20268-K Bylaws or fiscal year changed³⁶
7. May 11, 20268-K Shareholder vote³⁷
8. Apr 14, 20268-K Entered a material agreement; Unregistered sale of shares; Change in control³⁸
9. Apr 9, 20268-K Other events³⁹
10. Apr 3, 20268-K Other events⁴⁰
11. Feb 18, 20268-K Bylaws or fiscal year changed⁴¹
12. Feb 12, 20268-K Executive or director change⁴²
13. Nov 6, 2019New chief executive Mel Sorensen becomes CEO¹⁴

Calendar

When it reported results

1. Aug 14, 2024Reported quarterly or annual results⁴³
2. May 13, 2024Reported quarterly or annual results⁴⁴
3. Mar 28, 2024Reported quarterly or annual results⁴⁵
4. Nov 14, 2023Reported quarterly or annual results⁴⁶
5. Oct 31, 2023Reported quarterly or annual results⁴⁷
6. Aug 14, 2023Reported quarterly or annual results⁴⁸
7. Aug 10, 2023Reported quarterly or annual results⁴⁹
8. May 11, 2023Reported quarterly or annual results⁵⁰

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

211 filings to the SEC since October 2021: 5 annual reports, 14 quarterly reports, 56 major events, 67 insider forms, 30 large holders, 2 private raises, 37 other. The latest 20:

1. Aug 14, 2026SCHEDULE 13G/A EDGAR
2. Aug 7, 2026EFFECT EDGAR
3. Aug 5, 20264 EDGAR
4. Aug 5, 20264 EDGAR
5. Aug 5, 20264 EDGAR
6. Aug 5, 20264 EDGAR
7. Aug 5, 20264 EDGAR
8. Aug 5, 20264 EDGAR
9. Aug 4, 202615-12G EDGAR
10. Aug 4, 2026POS AM EDGAR
11. Aug 4, 2026S-8 POS EDGAR
12. Aug 4, 2026S-8 POS EDGAR
13. Aug 4, 20268-K EDGAR
14. Jul 31, 20268-K EDGAR
15. Jul 13, 2026DEFA14C EDGAR
16. Jul 13, 20268-K EDGAR
17. Jul 7, 2026DEFA14C EDGAR
18. Jul 7, 20268-K EDGAR
19. Jul 2, 2026DEFM14C EDGAR
20. Jun 11, 2026SCHEDULE 13D EDGAR

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

22 open-market trades by officers, directors and large owners since October 2021: 14 buys and 8 sales. Grants, option exercises and gifts are left out.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

• Ikarian Capital, LLCSCHEDULE 13G/A, 2 filings Feb 14, 2025 to Aug 14, 2026⁵¹
• Parvinder S. HyareSCHEDULE 13D, 1 filing Jun 11, 2026⁵²
• Emerald Bioventures, LLCSCHEDULE 13D/A, 2 filings Apr 27, 2026 to May 29, 2026⁵³
• Nancy T. ChangSCHEDULE 13D, 1 filing Apr 10, 2026⁵⁴
• Rochel SofferSC 13G, 1 filing May 16, 2024⁵⁵
• Yair SchneidSC 13G/A, 3 filings Jan 17, 2024 to May 16, 2024⁵⁶
• ALPHA PHARMA Investments LLCSC 13G, 1 filing Apr 16, 2024⁵⁷
• Altamont Pharmaceutical Holdings, LLCSC 13G/A, 2 filings Nov 13, 2023 to Apr 3, 2024⁵⁸
• Sofinnova Venture Partners IX, L.P.SC 13D/A, 2 filings Feb 6, 2023 to Feb 20, 2024⁵⁹
• SECTORAL ASSET MANAGEMENT INCSC 13G/A, 2 filings Feb 13, 2023 to Feb 14, 2024⁶⁰
• GSA CAPITAL PARTNERS LLPSC 13G, 1 filing Jan 2, 2024⁶¹
• Blackstone Holdings I/II GP L.L.C.SC 13D/A, 3 filings Feb 11, 2022 to Dec 4, 2023⁶²
• Novo Holdings A/SSC 13G/A, 2 filings Feb 2, 2022 to Jun 28, 2023⁶³
• James E. FlynnSC 13G, 1 filing Feb 28, 2023⁶⁴
• CITADEL ADVISORS LLCSC 13G/A, 2 filings Dec 27, 2021 to Feb 14, 2022⁶⁵
• Novartis Bioventures LtdSC 13G/A, 1 filing Feb 11, 2022⁶⁶
• Rosalind Advisors, Inc.SC 13G, 1 filing Feb 11, 2022⁶⁷
• ADAGE CAPITAL PARTNERS GP, L.L.C.SC 13G/A, 1 filing Feb 10, 2022⁶⁸
• Orin HirschmanSC 13G/A, 1 filing Oct 20, 2021⁶⁹

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

Funding

Where the company's money came from, by calendar year: private offerings filed with the SEC, federal grants, loans, contracts and other assistance from USAspending.gov, and PPP loans from the SBA. Each bar links to the records below.

Private raises

Private offerings the company reported to the SEC on Form D. The amount is what the latest filing says was sold so far, charted in the year of the first sale. Covers filings since Oct 1, 2021.

1. Dec 30, 2024Raised $2.7 million in a private offering of equity⁷¹ Form D: 18 investors so far Form D
2. Dec 30, 2024Raised $2.9 million in a private offering of equity³⁰ Form D: 8 investors so far Form D

SEC filer profile

How Galera Therapeutics, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

• Name on EDGARGalera Therapeutics, Inc.¹
• CIK0001563577
• Employer ID (EIN)46-1454898⁴
• Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; not a shell company⁴
• Incorporated inDelaware⁴
• Fiscal year endsDecember 31¹
• Industry code (SIC)2834 Pharmaceutical Preparations¹
• SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance¹
• Business address101 Lindenwood Drive, Suite 225, Malvern, PA 19355¹
• Phone610-725-1500¹
• Shares outstanding160,429,783 as of May 12, 2026¹³
• Public float$1.5M as of Jun 30, 2025⁴
• AuditorKPMG LLP, Philadelphia, Pennsylvania PCAOB ID 185; no auditor attestation of internal control over financial reporting⁴
• On EDGAR sinceDec 10, 2012¹
• Filings373 in all: 4 (115), 8-K (76), 3 (34), 10-Q (20), SC 13G/A (18), SC 13G (16), 425 (12), 10-K (7)¹
  All 45 form types

  D (7), DEF 14A (7), CORRESP (4), DEFA14A (4), DRS/A (3), EFFECT (3), SC 13D/A (3), SCHEDULE 13D (3), UPLOAD (3), 144 (2), 8-A12B (2), ARS (2), DEFA14C (2), DRSLTR (2), PRE 14A (2), S-8 (2), S-8 POS (2), SC 13D (2), SEC STAFF LETTER (2), 15-12G (1), 25-NSE (1), 4/A (1), 424B4 (1), 424B5 (1), 5 (1), 8-K/A (1), CERT (1), DEFM14C (1), DRS (1), NT 10-Q (1), POS AM (1), S-1 (1), S-1/A (1), S-3 (1), SCHEDULE 13D/A (1), SCHEDULE 13G (1), SCHEDULE 13G/A (1)

• Latest filingsAnnual report (10-K) Mar 19, 2026
  Quarterly report (10-Q) May 14, 2026
  Proxy statement (DEF 14A) Apr 20, 2026
  Latest 8-K (8-K) Aug 4, 2026

Securities registered for trading

From the cover page of the 10-K filed Mar 19, 2026 (Section 12(b) of the Exchange Act).⁴

Risk factors and legal proceedings

The risks Galera Therapeutics, Inc. names in Item 1A of its 10-K filed Mar 19, 2026: 40 risks under these headings, as written.⁴

• Risks Related to Our Financial Position and Capital Needs
• We have incurred significant operating losses since our inception and anticipate that we will incur continued losses for the foreseeable future.
• Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidate.
• Risks Related to the Discovery and Development of Our Product Candidate
• We are heavily dependent on the success of our product candidate, tilarginine, which has not received regulatory approval. If development of our product candidate is unsuccessful, we may be unable to obtain required regulatory approvals and be unable to commercialize our product candidate on a timely basis, if at all.
• We rely, and will continue to rely, on third parties to conduct our clinical trials for our product candidate, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials.
• Success in preclinical studies or earlier clinical trials may not be indicative of results in future clinical trials.
• Our product candidate may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval or result in significant negative consequences following marketing approval, if any.
• The biopharmaceutical industries are subject to extensive regulatory obligations and policies that may be subject to significant and abrupt change, including due to judicial challenges, election cycles, and resulting regulatory updates and changes in policy priorities.
• Risks Related to Competition, Retaining Key Employees and Managing Growth
• Our future success depends on our ability to retain key executives and to attract, retain and motivate qualified personnel.
• Risks Related to Intellectual Property

Legal proceedings

From time to time, we may be involved in claims and proceedings arising in the course of our business. The outcome of any such claim or proceeding, regardless of the merits, is inherently uncertain.

The opening of Item 3, Legal Proceedings.⁴